Table 4.
Risk factors associated with recurrence
| Characteristic | Recurrence (n = 3,039) | No recurrence (n = 10,289) | P-value |
|---|---|---|---|
| Sex | 0.003 | ||
| Male | 1,896 (62.4) | 6,110 (59.4) | |
| Female | 1,143 (37.6) | 4,179 (40.6) | |
| Age | 0.757 | ||
| <60 years | 1,267 (41.7) | 4,322 (42.0) | |
| ≥60 years | 1,772 (58.3) | 5,967 (58.0) | |
| Family history | 0.068 | ||
| No | 2,878 (94.7) | 9,652 (93.8) | |
| Yes | 161 (5.3) | 637 (6.2) | |
| Location | <0.001 | ||
| Right-sided colon | 631 (20.7) | 2,456 (23.9) | |
| Left-sided colon | 883 (29.1) | 3,151 (30.6) | |
| Rectum | 1,525 (50.2) | 4,682 (45.5) | |
| Differentiation status | <0.001 | ||
| High | 267 (8.8) | 1,272 (12.4) | |
| Moderate | 2,344 (77.1) | 7,903 (76.8) | |
| Poor/undifferentiated | 428 (14.1) | 1,115 (10.8) | |
| pT category | <0.001 | ||
| T1 | 101 (3.3) | 1,147 (11.1) | |
| T2 | 231 (7.6) | 1,590 (15.5) | |
| T3 | 1,575 (51.8) | 4,871 (47.3) | |
| T4 | 1,132 (37.2) | 2,681 (26.1) | |
| pN category | <0.001 | ||
| N0 | 1,220 (40.1) | 6,816 (66.2) | |
| N1 | 1,030 (33.9) | 2,404 (23.4) | |
| N2 | 789 (26.0) | 1,069 (10.4) | |
| pM category | <0.001 | ||
| M0 | 2,112 (69.5) | 9,352 (90.9) | |
| M1 | 927 (30.5) | 937 (9.1) | |
| Clinical stage | <0.001 | ||
| I | 219 (7.2) | 2,336 (22.7) | |
| II | 739 (24.3) | 4,149 (40.3) | |
| III | 1,154 (38.0) | 2,867 (27.9) | |
| IV | 927 (30.5) | 937 (9.1) | |
| Pathological subtypes | <0.001 | ||
| Adenocarcinoma | 2,652 (87.3) | 9,092 (88.4) | |
| MA and SRCCa | 293 (9.6) | 794 (7.7) | |
| Othersb | 94 (3.1) | 403 (3.9) | |
| Surgical margin | <0.001 | ||
| Negative | 2,885 (94.9) | 9,919 (96.4) | |
| Positive | 154 (5.1) | 370 (3.6) | |
| Chemotherapy | <0.001 | ||
| No | 1,295 (42.6) | 6,042 (58.7) | |
| Yes | 1,744 (57.4) | 4,247 (41.3) |
a
Mucinous adenocarcinoma and signet-ring cell carcinoma.
b
Other pathologic subtypes included gastrointestinal stromal tumors, adenosquamous carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, malignant melanoma, lymph hematopoietic neoplasms, and gastrointestinal mesenchymal tumors.